Cass Pharmaceuticals
CASS Pharmaceuticals: Swift provider of rapid-acting insulin for diabetes management.
Founded
2020CASS Pharmaceuticals: Swift provider of rapid-acting insulin for diabetes management.
CASS Pharmaceuticals, founded with a mission to improve diabetes management, focuses on providing rapid-acting insulin for diabetic patients. The company's vision is to enhance the quality of life for individuals with diabetes through innovative and effective insulin solutions. Their core product, rapid-acting insulin, is designed to help regulate blood sugar levels swiftly, addressing one of the most critical needs in diabetes care. CASS Pharmaceuticals primarily targets the global market of diabetic patients, which is expected to grow significantly in the coming years.
Notable figures affiliated with CASS Pharmaceuticals include leading endocrinologists and diabetes researchers who contribute to the development and refinement of their insulin products. The company has attracted significant investment from healthcare-focused venture capital firms, underscoring the potential impact of their offerings. Key achievements include successful clinical trials demonstrating the efficacy and safety of their rapid-acting insulin. Overall, CASS Pharmaceuticals has made a substantial impact on diabetes management, providing essential solutions that improve patient outcomes and quality of life.
Companies similar to Cass Pharmaceuticals include Cassian Solutions, Sensulin, Filana Therapeutics and Glycostasis.
Cass Pharmaceuticals was founded in 2020.
Cass Pharmaceuticals' headquarters is located in Franklin, TN, US.
Cass Pharmaceuticals' most recent funding round was for $2M (USD) in October 2022.
As of Oct 21, 2022, Cass Pharmaceuticals has raised a total of $2M (USD).
Cass Pharmaceuticals has 5 employees as of Feb 5, 2024.
Filana Therapeutics
